BRIEF-Eiger announces positive phase 2 data for the study of liver diseases (AASLD)
November 14, 2016 at 08:39 AM EST
* Eiger - low dose LNF + RTV with peg IFN achieves most rapid and profound viral load decline, with highest rate of HDV-RNA PCR-negativity on treatment
